Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 33Psychedelics and Drug StudiesSynthesis and bioactivity of alkaloidsAlkaloids: synthesis and pharmacology

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index; 36 of the 59 sources its claims cite were checked for support.

Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects

Open access

Abstract

Background: There is growing scientific evidence for the therapeutic benefits of the Amazonian plant-based psychedelic “ayahuasca” for neuropsychiatric disorders such as depression and anxiety. However, there are certain challenges when incorporating botanical ayahuasca into biomedical research and clinical therapy environments. Formulations inspired by ayahuasca, which contain specific and standardized active components, are a potential remedy. Methods: We investigated subjective acute and persisting effects of a novel formulation containing the reversible monoamine oxidase inhibitor harmine (orodispersible tablet containing 100 mg MAO-I) and N,N-dimethyltryptamine (incremental intranasal dosing of up to 100 mg DMT), compared with two other conditions, namely harmine alone and placebo, in a crossover RCT in 31 healthy male subjects. Results: DMT + harmine, but not harmine alone, induced a psychedelic experience assessed with the 5D-ASC rating scale [global score: F(2,60) = 80.21, p < 0.001] and acute experience sampling items over time, characterized by psychological insights [PIQ, F(2,58.5) = 28.514, p < 0.001], emotional breakthroughs [EBI, F(2,60) = 26.509, p < 0.001], and low scores on the challenging experience questionnaire [CEQ, F(2,60) = 12.84, p < 0.001]. Participants attributed personal and spiritual significance to the experience (GSR) with mainly positive persisting effects (PEQ) at 1- and 4-months follow-up. Acute drug effects correlated positively with persisting effects. We found no changes in trait measures of personality, psychological flexibility, or general well-being, and no increases in psychopathology (SCL-90-R) were reported. Discussion and Conclusion: Our results suggest that the experience induced by the standardized DMT + harmine formulation induces a phenomenologically rich psychedelic experience, demonstrates good psychological safety and tolerability, is well tolerated, and induces beneficial psychological processes that could possibly support psychotherapy. Further studies are required to investigate the psychotherapeutic potential in patients. Copyright © 2024 Aicher, Mueller, Dornbierer, Suay, Elsner, Wicki, Meling, Caflisch, Hempe, Steinhart, Mueller, Von Rotz, Kleim and Scheidegger.

Overview

CoChat Summary

## TL;DR

This randomized controlled crossover trial in 31 healthy men found that the combined DMT + harmine formulation, but not harmine alone, produced a psychedelic experience with psychological insights, emotional breakthroughs, and mainly positive persisting effects at 1 and 4 months. The study suggests potential psychotherapy-relevant effects and good psychological tolerability, but it was conducted in a non-therapeutic setting and did not show trait changes or increased well-being.

## Key findings

  • In 31 healthy male participants, DMT + harmine induced strong acute psychedelic effects on the 5D-ASC global score compared with both harmine and placebo: F(2,60) = 80.21, p < 0.001; all 11 5D-ASC subscales were significantly increased.
  • DMT + harmine increased psychological insight and emotional breakthrough: PIQ global score F(2,58.5) = 28.51, p < 0.001; EBI F(2,60) = 26.51, p < 0.001. It also increased challenging experiences relative to the other conditions, but CEQ scores remained low overall.
  • Persisting effects at 1 and 4 months were mainly positive across PEQ domains, with significant positive vs negative effects in attitude toward life, mood, social effects, and behavior change (combined follow-up timepoints: r = 0.83, 0.57, 0.46, and 0.78, all p < 0.001).
  • No increases were found in trait measures of acceptance/action, cognitive flexibility, nature relatedness, well-being, or openness, and no decreases in neuroticism were found; no increases in psychopathology on the SCL-90-R were reported.

## Methods

  • Randomized, double-blind, placebo-controlled crossover trial with three conditions: DMT + harmine (DMT/HAR), harmine only (HAR), and placebo (PLA), separated by at least 2 weeks.
  • Sample: 31 healthy male subjects completed all 3 intervention days; 37 were recruited and 6 dropped out. Mean age was 25.39 ± 4.21 years.
  • Main analysis used mixed-model ANOVAs for acute/retrospective outcomes, Wilcoxon tests for 2 timepoints, Friedman tests with post-hoc Dunn-Bonferroni tests for 3 timepoints, and correlations between acute and persisting effects.

## Limitations

  • The paper states that it did not assess intranasal DMT alone, so the specific pharmacological effects of intranasal DMT remain unclear.
  • The authors note that blinding may have been weakened by the psychedelic effects, expectations may have influenced outcomes, and the sample was WEIRD and all male, limiting generalizability.
  • The study setting was pharmacologically and neurobehaviorally oriented rather than therapeutic or integration-focused, which the paper says may have reduced introspection and attenuated subjective effects; additionally, only 22 of 31 participants completed all follow-up trait assessments.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2023.1302559

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

32 tests recomputed · 0 with the reported and recomputed p on opposite sides of .05

Figures

Figure 1 Overview of Study Design, Study Visits and Intervention Days Procedure. HAR = harmine (or placebo respectively); DMT, N = N-dimethyltryptamine (or placebo respectively). Drug conditions were randomized, double-blind, crossover: (1) Harmine 100 mg buccal + DMT 100 mg (10* 10 mg) intranasal; (2) Harmine 100 mg buccal + Placebo intranasal; (3) Placebo buccal + Placebo intranasal. Intranasal: Repeated intermittent dosing. Washout-phase of at least 2 weeks between intervention days. A = acute assessment; K = keywords experience sampling; P = post-acute assessment. A&K experience sampling was assessed with VAS (visual analog scale) items. SCL-90-R: Symptom check list; 5D-ASC = 5 dimensions altered states of consciousness rating scale; PIQ = psychological insights questionnaire; EBI = emotional breakthrough inventory; CEQ = challenging experience questionnaire; PEQ = persisting effects questionnaire. Only assessments relevant for this publication are shown.
Figure 1 Overview of Study Design, Study Visits and Intervention Days Procedure. HAR = harmine (or placebo respectively); DMT, N = N-dimethyltryptamine (or placebo respectively). Drug conditions were randomized, double-blind, crossover: (1) Harmine 100 mg buccal + DMT 100 mg (10* 10 mg) intranasal; (2) Harmine 100 mg buccal + Placebo intranasal; (3) Placebo buccal + Placebo intranasal. Intranasal: Repeated intermittent dosing. Washout-phase of at least 2 weeks between intervention days. A = acute assessment; K = keywords experience sampling; P = post-acute assessment. A&K experience sampling was assessed with VAS (visual analog scale) items. SCL-90-R: Symptom check list; 5D-ASC = 5 dimensions altered states of consciousness rating scale; PIQ = psychological insights questionnaire; EBI = emotional breakthrough inventory; CEQ = challenging experience questionnaire; PEQ = persisting effects questionnaire. Only assessments relevant for this publication are shown.CC BY · PubMed Central
Figure 2 Dynamic Experience Sampling of the Acute Subjective Drug Effects Over Time. Experience sampling: Dynamic ratings of the acute subjective drug effects over time for the 3 conditions DMT/HAR, HAR, PLA. Single word acute items (intensity, liking, disliking, frightening, arousing, relaxing), full sentence acute items (loss of control, letting go, elementary imagery, complex imagery), and ambiguity (how easy/difficult was it to answer the questions) were assessed before drug administration at day baseline (bl), at t0 (right before initial DMT/placebo administration, 30 min after harmine/placebo administration), and every 30 min until t240, and at t300. Psychedelic and empathogenic keywords (ten single words) and body boundaries were assessed at day baseline (bl), t0, and every 60 min until t300. Mean values and standard errors (SEs) are shown.
Figure 2 Dynamic Experience Sampling of the Acute Subjective Drug Effects Over Time. Experience sampling: Dynamic ratings of the acute subjective drug effects over time for the 3 conditions DMT/HAR, HAR, PLA. Single word acute items (intensity, liking, disliking, frightening, arousing, relaxing), full sentence acute items (loss of control, letting go, elementary imagery, complex imagery), and ambiguity (how easy/difficult was it to answer the questions) were assessed before drug administration at day baseline (bl), at t0 (right before initial DMT/placebo administration, 30 min after harmine/placebo administration), and every 30 min until t240, and at t300. Psychedelic and empathogenic keywords (ten single words) and body boundaries were assessed at day baseline (bl), t0, and every 60 min until t300. Mean values and standard errors (SEs) are shown.CC BY · PubMed Central
Figure 3 Participant’s Retrospective Ratings on the 5D-ASC Questionnaire. 5-Dimensions Altered States of Consciousness rating scale (5D-ASC) for all three drug conditions (DMT/HAR, HAR, PLA) with boxplots for all subscales: experience of unity, spiritual experience, blissful state, insightfulness, disembodiment, impaired cognition and control, anxiety, elementary imagery, complex imagery, audio-visual synesthesia, changed meaning of percepts. Spider plot visualizations of the 11 subscales and the 5 dimensions of the 5D-ASC for comparability with other trials using the same scale can be found in the Supplementary Figure S1.
Figure 3 Participant’s Retrospective Ratings on the 5D-ASC Questionnaire. 5-Dimensions Altered States of Consciousness rating scale (5D-ASC) for all three drug conditions (DMT/HAR, HAR, PLA) with boxplots for all subscales: experience of unity, spiritual experience, blissful state, insightfulness, disembodiment, impaired cognition and control, anxiety, elementary imagery, complex imagery, audio-visual synesthesia, changed meaning of percepts. Spider plot visualizations of the 11 subscales and the 5 dimensions of the 5D-ASC for comparability with other trials using the same scale can be found in the Supplementary Figure S1.CC BY · PubMed Central
Figure 4 Retrospective Assessment of the Subjective Experience. Retrospective assessment of the subjective experience induced by the three drug conditions DMT/HAR = DMT + harmine, HAR = harmine only, PLA = placebo. (A) PIQ = psychological insights questionnaire; AMP = avoidance and maladaptive patterns insights; GAP = goals and adaptive patterns insights, global score; (B) EBI = emotional breakthrough inventory; (C) CEQ = challenging experience questionnaire fear, grief, physical distress, insanity, isolation, death, paranoia, global score.
Figure 4 Retrospective Assessment of the Subjective Experience. Retrospective assessment of the subjective experience induced by the three drug conditions DMT/HAR = DMT + harmine, HAR = harmine only, PLA = placebo. (A) PIQ = psychological insights questionnaire; AMP = avoidance and maladaptive patterns insights; GAP = goals and adaptive patterns insights, global score; (B) EBI = emotional breakthrough inventory; (C) CEQ = challenging experience questionnaire fear, grief, physical distress, insanity, isolation, death, paranoia, global score.CC BY · PubMed Central
Figure 5 Persisting Effects and Symptoms. (A) PEQ (persisting effects) assessed at 1 month (n = 26) and 4 months (n = 28) follow-up. (B) SCL-90-R (symptom checklist) assessed at baseline (n = 31), 1 month (n = 25), and 4 months (n = 28) follow-up: somatization, obsessive compulsion, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism.
Figure 5 Persisting Effects and Symptoms. (A) PEQ (persisting effects) assessed at 1 month (n = 26) and 4 months (n = 28) follow-up. (B) SCL-90-R (symptom checklist) assessed at baseline (n = 31), 1 month (n = 25), and 4 months (n = 28) follow-up: somatization, obsessive compulsion, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism.CC BY · PubMed Central
Figure 6 Significance of the Experience Rated at 1 Month Follow-up. N = 25. Attribution of subjective significance (GSR) of the experience at 1 month follow-up: Personal meaning (A), spiritual significance (B), change in sense of personal well-being and life satisfaction (C), shown in number and percentage of participants. High vs. low sensitivity group (median split according to maximum subjective intensity ratings) are marked in gray tones, participants of the high sensitivity group generally reporting higher significance. Items and answer options were as follows: (A) “How personally meaningful was the experience?” (1 = no more than routine, everyday experiences, 2 = similar to meaningful experiences that occur on average once or more a week; 3 = similar to meaningful experiences that occur on average once a month; 4 = similar to meaningful experiences that occur on average once a year; 5 = similar to meaningful experiences that occur on average once every 5 years; 6 = among the 10 most meaningful experiences of my life; 7 = among the 5 most meaningful experiences of my life; and 8 = the single most meaningful experience of my life). (B) “Indicate the degree to which the experience was spiritually significant to you.” (1 = not at all, 2 = slightly, 3 = moderately, 4 = very much, 5 = among the 5 most spiritually significant experiences of my life, and 6 = the single most spiritually significant experience of my life). (C) “Do you believe that the experience and your contemplation of that experience have led to change in your current sense of personal well-being or life satisfaction?” (7 = increased very much,6 = increased moderately, 5 = increased slightly, 4 = no change, 3 = decreased slightly, 2 = decreased moderately, and 1 = decreased very much). GSR at 4 months follow-up can be found in the Supplementary Figure S2.
Figure 6 Significance of the Experience Rated at 1 Month Follow-up. N = 25. Attribution of subjective significance (GSR) of the experience at 1 month follow-up: Personal meaning (A), spiritual significance (B), change in sense of personal well-being and life satisfaction (C), shown in number and percentage of participants. High vs. low sensitivity group (median split according to maximum subjective intensity ratings) are marked in gray tones, participants of the high sensitivity group generally reporting higher significance. Items and answer options were as follows: (A) “How personally meaningful was the experience?” (1 = no more than routine, everyday experiences, 2 = similar to meaningful experiences that occur on average once or more a week; 3 = similar to meaningful experiences that occur on average once a month; 4 = similar to meaningful experiences that occur on average once a year; 5 = similar to meaningful experiences that occur on average once every 5 years; 6 = among the 10 most meaningful experiences of my life; 7 = among the 5 most meaningful experiences of my life; and 8 = the single most meaningful experience of my life). (B) “Indicate the degree to which the experience was spiritually significant to you.” (1 = not at all, 2 = slightly, 3 = moderately, 4 = very much, 5 = among the 5 most spiritually significant experiences of my life, and 6 = the single most spiritually significant experience of my life). (C) “Do you believe that the experience and your contemplation of that experience have led to change in your current sense of personal well-being or life satisfaction?” (7 = increased very much,6 = increased moderately, 5 = increased slightly, 4 = no change, 3 = decreased slightly, 2 = decreased moderately, and 1 = decreased very much). GSR at 4 months follow-up can be found in the Supplementary Figure S2.CC BY · PubMed Central

Verification

Claims the paper makes

22 Valid · 2 Not valid · 7 Not checked · 99 Own results and interpretations

46 more claims · 3 with their cited sources checked

Create a free account to see all 130 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 58
  • Probably not a substantial claim. 28

Create a free account to see these claims.

Statistics that don’t add up

Each reported p-value recomputed from its test statistic and degrees of freedom.

1 of 1

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • Doesn’t add upF(2, 60) = 3.94reported p = .023 · recomputed p = .025

    “F(2, 60) = 3.94, p = .023”

  • ConsistentF(2, 60) = 80.21reported p < .001 · recomputed p < .001

    “F(2,60) = 80.21, p < .001”

  • ConsistentF(2, 58.5) = 28.514reported p < .001 · recomputed p < .001

    “F(2,58.5) = 28.514, p < .001”

  • ConsistentF(2, 60) = 26.509reported p < .001 · recomputed p < .001

    “F(2,60) = 26.509, p < .001”

  • ConsistentF(2, 60) = 12.84reported p < .001 · recomputed p < .001

    “F(2,60) = 12.84, p < .001”

5 of 32 · the rest aren’t loaded

27 more recomputed tests

Create a free account to see every test the Stats check recomputed.

See all tests — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 89 references

Research works printed but not linked: 3

  1. Franke, 2002, SCL-90-R: Symptom-Checkliste von L.R. Derogatis: Deutsche Version
  2. 2021, R: A language and environment for statistical computing
  3. 2022, World mental health report

Cited by

See all 33

Metadata

Authors
Aicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., Mueller, J., Von Rotz, R., Kleim, B., & Scheidegger, M.
Affiliations
  • University of Zurich (CH)
  • IMT School for Advanced Studies Lucca (IT)
  • University of Freiburg (DE)
Corresponding author
Aicher, Helena D.
Venue
Frontiers in Psychiatry
Published
2024-01-08
Volume
14
Pages
1302559-1302559
ISSN
1664-0640 (ISSN-L)
OpenAlex
W4390825728
Cited by
33
References
89
Citations by year
2026: 7 · 2025: 18 · 2024: 8
FWCI
16.48
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • OSF Preprints (OSF Preprints) (submittedVersion)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • ETH Zürich Research Collection
  • Zurich Open Repository and Archive (University of Zurich)
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (191935)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Physical Sciences › Chemistry › Organic Chemistry › Synthesis and bioactivity of alkaloids
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
Keywords
N,N-dimethyltryptamine, harmine, monoamine oxidase inhibitors, psychedelic experience, psychological safety, psychological flexibility, psychological well-being, psychological insight, spiritual meaning, depression, anxiety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects. https://app.cochat.ai/papers/10.3389/fpsyt.2023.1302559
The paper
Aicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., Mueller, J., Von Rotz, R., Kleim, B., & Scheidegger, M. (2024). Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2023.1302559

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.